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Abstract
There are many claims surrounding the health benefits of consuming green tea, some of which
involve its use in the treatment of medical conditions as wide ranging as cancer, diabetes, and
neurodegenerative disorders. The desire for the use of non-toxic and natural drugs to treat
various diseases makes any health-benefitting claims about green tea and its components
important to investigate for their potential public health benefits. I conducted a critical review of
the research literature on green tea and its effects on human health and synthesized the results.
There is convincing epidemiological evidence pointing to the health benefits derived from
consumption of green tea, but National Institutes of Health (NIH)-funded clinical trials are few
in number and have produced only modest results. The main biologically active compound in
green tea, epigallocatechin gallate (EGCG), does not demonstrate specific binding to biological
molecules and varies greatly in its concentration in green tea. EGCG also has a weak, but
notable, relationship between dose and maximum plasma concentration in humans; however,
most concentrations of EGCG used in laboratory studies are far beyond the physiologically
achievable levels. Additionally, there is evidence that high doses of EGCG may lead to liver
damage. Finally, green tea polyphenols are implicated in a vast number of interactions, but these
are not well understood and suggest the possibility of pan-assay interference. Without clear
mechanistic evidence or reliable dosing strategies, it is unlikely that green tea will be suitable for
pharmaceutical uses in the treatment of human disease.
Introduction
Green tea is claimed by the news media and scientists alike to be a source of health benefits for
many conditions in humans. However, with the supposed health benefits of green tea ranging
from ultraviolet light protection to memory improvement to weight management, it can be
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difficult to separate fact from fiction. Scientists have a renewed interest in utilizing natural
remedies in modern medicine, and nutrition researchers have begun to focus on determining the
role of bioactive compounds in the pathology of diseases (Kris-Etherton and Keen 2002). In
recent years, the research focus has shifted towards the role of bioactive compounds in the
prevention and treatment of diseases (Khan and Mukhtar 2013; Kris-Etherton and Keen 2002;
McKay and Blumberg 2002). For many centuries, tea has been considered one of the most
beneficial sources of bioactive compounds (Narotzki et al. 2011; Serafini et al. 2011). In 1211,
for example, the Japanese Zen priest Yeisai published the book Kitcha-Yojoki, translated as “Tea
and Health Promotion”, describing the pharmaceutical applications of green tea, Camellia
sinensis Theaceae (Suzuki et al. 2012). Much has changed since 1211, but the public’s
fascination with tea and its health benefits have remained. Because tea is the most consumed
beverage in the world aside from water, even small beneficial health effects in humans could
result in significant effects in global public health (Kuriyama et al. 2006; Rimm and Stampfer
2004).
Numerous epidemiological studies provide support for green tea's role in preventing and
treating many disorders (Hertog et al. 1995; Iso et al. 2006; Kris-Etherton and Keen 2002;
Kuriyama et al. 2006; Mozaffari-Khosravi et al 2013; Odegaard et al. 2008; Sesso et al. 1999;
Yang et al 2004). These epidemiological studies suggest a relationship between drinking green
tea and positive health outcomes; however, epidemiological studies are not capable of
determining if green tea is directly causing these outcomes. While many epidemiological studies
provide valuable insight into real-world effects of green tea consumption on human health, many
confounding variables exist (Riemersma et al. 2001). These variables include gender, weight,
diet, activity, smoking, coffee consumption, genetics, etc. Though epidemiologists work to

4
control many of these confounding variables, it is not possible to completely control for all of
them. A more direct way to evaluate green tea’s health benefits is to determine: 1) the specific
components in green tea producing the effects, i.e., bioactive molecules; 2) how these bioactive
molecules produce the effects, i.e., their mechanism of action; and 3) the availability of these
molecules to cells in the body, i.e., their bioavailability. These characteristics can only be
evaluated in clinical and laboratory studies.
There are numerous bioactive molecules in green tea, but most attention has focused on
polyphenols. Green tea is rich in polyphenols, which are antioxidant compounds capable of
neutralizing highly reactive molecules called free radicals (Kim et al. 2014; Quideau et al. 2011).
Although best known for their antioxidant properties, polyphenols may have antiviral,
antibacterial, and gene regulation properties (Kim et al. 2014; Kozłowska and Szostak-Węgierek
2014). The most studied polyphenol in green tea is epigallocatechin gallate (EGCG) (Williamson
and Manach 2005). A recent search for “green tea” in the major biomedical literature database
PubMed produced over 5,000 articles, and a search for “EGCG” yielded more than 4,000
articles. A quick scan of the review articles published in 2014 alone revealed studies of green tea
within the context of various cancers, infectious diseases, inflammation, oral health, cognitive
mood and function, neurodegenerative diseases, and obesity.
The observation of so many different biological effects purportedly arising from the
ingestion of green tea raises concerns about the specificity of EGCG (Table 1). Recently, a new
classification of chemicals deemed “pan-assay interfering” compounds, or PAINS, has cast
doubt upon the usefulness of compounds such as EGCG as potential medical therapies (Baell and
Walters 2014). Alternative names for PAINS include “frequent-hitters” and “promiscuous
compounds”, as they often appear in a variety of unrelated pathways and systems (Bajorath
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2014). Effective drugs are characterized by their ability to bind to a specific site on a protein,
which thereby induces activation or inhibition of that particular protein (or pathway).
Researchers measure the ability of drugs to bind proteins using various assays, but it has been
suggested that PAINS are capable of "tricking" these assays into giving false-positive results
(Baell and Walters 2014). PAINS may bind to a protein, but they do not bind in a specific
location required for drug-like action, and therefore the binding signal may be an artifact and not
an indication of specific biological activity (Baell and Walters 2014). EGCG has been flagged as
a potential PAIN compound due to its apparent omnipresence in biological systems (Baell and
Walters 2014). Some researchers have suggested that plant phytochemicals such as EGCG may
act promiscuously in humans by altering membrane protein function and thus merely appear to
be pervasively active (Ingólfsson et al. 2014). The pharmaceutical industry has understood for
some time the importance of classifying these “bad actors”; however, researchers continue to
publish papers ascribing the potential pharmaceutical applications of compounds that do not
demonstrate specific biological activity (Baell 2010). Is it possible for one beverage to be a
therapy for everything from prostate cancer to sunburn? Or, is it more likely that green tea’s
apparent universal application is because it is a PAIN?
In some cases, researchers propose cellular and molecular mechanisms by which green
tea may produce a health benefit. EGCG’s classification as an antioxidant, however, only
heightens concerns of non-specific interactions not suitable for pharmaceutical drug
classification. Antioxidants act to neutralize the harmful effects of reactive oxygen species
(ROS), such as peroxides, and reactive nitrogen species (NOS), such as peroxynitrate (Anissi et
al. 2013). ROS and NOS contain extra electrons that attack other molecules, which can result in
damage to proteins, DNA, etc. (Sullivan and Chandel 2014). Antioxidants, such as EGCG and
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other green tea components, neutralize ROS and NOS, and thus act to prevent damage by these
molecules (Sullivan and Chandel 2014). Pharmaceutical drugs are categorized in part by their
specific binding sites (Baell and Walters 2014); however, antioxidants are not specific in their
targets and therefore should not be classified as such.
Regardless of the mechanism of action, much of the scientific literature fails to address
the efficacy of green tea as a therapy. For example, the Unites States Department of Agriculture
found that concentrations of EGCG in 100 g samples of different green teas varied over 100-fold,
suggesting that its reliability as a consumable therapy is dubious at best (United States
Department of Agriculture 2013). Scientists conducting research into the mechanisms of action
utilized by EGCG often do not address the issue of EGCG’s concentration in the blood, which
studies show is not highly realted with dose (Ahn et al. 2014; Anita et al. 2014; Audomkasok et
al. 2014; Bashir et al. 2014; Delabre et al. 2015; Jeon et al. 2014; Lee et al. 2014a; MirandaHenriques et al. 2014; Nasri et al. 2013; Ohmori et al. 2014; Saleh et al. 2014; Table 2; Figure 1).
Additionally, the concentrations of EGCG examined in laboratory studies using cell cultures and
animal models, while meaningful within the scientific community, have little or no meaning to
the general public and are generally regarded as far higher than physiologically achievable levels
in humans (Lambert and Yang 2003). From a public health perspective, the conclusions drawn
from some of these studies are difficult to assess in regard to their application to a broader
audience.
In this thesis, I will examine epidemiological, clinical, and laboratory studies
investigating green tea’s effects on human health. I will also critically evaluate some of the
proposed mechanisms of action of green tea required to produce the beneficial results to
determine their feasibility within humans. Furthermore, I will assess EGCG’s potential
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classification as a pan-assay interfering compound. The goal of this thesis is to determine
whether green tea’s putative health benefits are scientifically supported — epidemiologically,
clinically, and biochemically.
Epidemiology of Green Tea Consumption
Epidemiology is the study of the distribution and determinants (causes/risk factors) of morbidity
(disease), injury, disability, and mortality within a population (Friis 2010). Epidemiologists use
surveillance and descriptive studies to determine and track the distribution of health problems
and analytical studies to investigate determinants (Friis 2010). Descriptive/surveillance
epidemiology aims to characterize the amount and distribution of health conditions within a
population, relying on the systematic collection, analysis, and distribution of information
pertaining to the disease occurrence (Friis 2010). Analytic epidemiology focuses on studying the
determinants of a disease within a population, examining the etiological (causal) factors linking
exposures and health conditions (Friis 2010). Both of these epidemiological approaches allow a
comprehensive examination of the incidence of a health condition within a community and
provide information for intervention.
Several epidemiological studies suggest that drinking green tea does have beneficial
health effects. One of the largest epidemiological studies on the health benefits of green tea is the
Ohsaki Study. From 1994 through 2005, the Ohsaki Study looked at the relationship between
green tea and mortality for 40,530 healthy Japanese adults aged 40 to 79 from the Miyagi
Prefecture in northeastern Japan (Kuriyama et al. 2006). A previous survey had reported that
42% of people in the Miyagi Prefecture regularly drank five or more cups of green tea daily
(Tsubono et al. 2001). The Ohsaki Study was designed as a prospective cohort, in which similar
individuals who differ in a certain factor, in this case green tea consumption, are followed over
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time to determine the effects of green tea consumption on a certain outcome, in this case
mortality. The Ohsaki Study found that those who reported drinking five or more cups of green
tea daily were significantly less likely to die during the period of observation than those who
drank less than one cup per day (Kuriyama et al. 2006).
One of the most prevalent claims relating to green tea’s health benefits is its ability to
lower the risk for cardiovascular disease. Cardiovascular disease refers to conditions relating to
the heart and the blood vessels and includes disorders such as arrhythmia, atherosclerosis
(buildup of plaque in arteries), hypertension, congenital heart defects, stroke, and heart attack
(Phinikaridou et al. 2013). As the leading cause of death in the United States, cardiovascular
disease is responsible for one in every four deaths and costs $108.9 billion annually in lost labor
and treatment (Heidenreich et al. 2011; Murphy et al. 2013). According to the Centers for
Disease Control and Prevention (CDC), 49% of Americans have at least one of the three major
risk factors for cardiovascular disease: high blood pressure, high LDL cholesterol, and smoking
(Valderrama et al. 2011). There are many epidemiological studies that focus on the role of green
tea in improving cardiovascular health.
The Ohsaki Study noted a decrease in deaths due to cardiovascular disease in green tea
drinkers. Women who drank five or more cups (1 cup = 100 mL) of green tea per day were 31%
less likely to die from cardiovascular diseases during the observation period than those who
drank less than one cup of green tea per day (Kuriyama et al. 2006). Another prospective cohort
study, The Seven Countries Study, followed sixteen cohorts over twenty-five years starting in
1960 and found that there was an inverse relationship between green tea intake and death due to
coronary heart disease (Hertog et al. 1995). The Boston Area Study found that the risk of heart
attack was reduced by 44% in those who drank one or more cups of green tea per day as
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compared to non-green tea-drinking controls (Sesso et al. 1999). Finally, a study conducted in
Taiwan found that consumption of between 120 mL and 599 mL of green tea daily reduced the
development of hypertension by 46% and that drinking over 600 mL daily reduced the risk of
hypertension by 65% (Yang et al. 2004). Each of these statistically significant results strengthens
claims that green tea is capable of reducing the incidence of cardiovascular disease.
As a strong risk factor for cardiovascular disease, diabetes has also been extensively
examined epidemiologically in the search for new, natural therapies. Diabetes mellitus results
from an inability to respond to and/or produce insulin, the hormone responsible for the uptake of
glucose by cells (Philippe and Raccah 2009). Type 1 diabetes is an autoimmune disorder,
whereas Type 2 is the progressive development of insulin resistance and secretion defects
leading to varying degrees of decreased β-cell function in the pancreas (Cnop et al. 2005; Liese
et al. 2013; U.K. Prospective 1995). Due to increased longevity and obesity, some researchers
predict that the global incidence of Type 2 diabetes, currently at 7%, will increase to 15% by
2030 (Boyle et al. 2010; Philippe and Raccah 2009; Wild et al. 2004). In the United States, 9.3%
of the population suffers from diabetes and 95% of new cases in adults are Type 2 diabetes
(Centers for Disease Control and Prevention 2014).
Epidemiological studies on diabetes vary in their conclusions on the effectiveness of
green tea as a potential therapy or preventative. One study of 17,000 Japanese men and women
found that drinking six or more cups of green tea daily led to a 33% reduced risk of developing
Type 2 diabetes (Iso et al. 2006). Another study found that drinking three cups of green tea daily
for four weeks decreased blood pressure in 39.6% of Iranian Type 2 diabetes patients
(Mozaffari-Khosravi et al. 2013). In contrast, the Singapore Chinese Health Study of over 36,000
participants saw no association between the consumption of more than one cup of green tea daily
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and a reduced risk for Type 2 diabetes (Odegaard et al. 2008). Therefore, it is not possible at
present to say whether green tea is effective at reducing risk for Type 2 diabetes, and additional
research will be necessary to elucidate the potential links between green tea and diabetes.
Cancer is another area in which many epidemiological investigations regarding green
tea’s health benefits have been conducted. Cancer results from the accumulation of mutations in
genes that regulate cell proliferation (Samuels et al. 2011). These mutations lead to uncontrolled
cell division without the normal checkpoints and regulation (Alberts et al. 2007). These
mutations may be inherited, increasing one's risk of cancer, or occur spontaneously as the result
of environmental exposure to tobacco or other chemical carcinogens, viruses, radiation, etc.
(O’Connor et al. 2011). One nine-year study, conducted in Japan in the 1990s, found that
females were statistically less likely to develop cancer of any type if they drank green tea
regularly; however, the effect was only significant in those drinking on average ten or more cups
of green tea daily (Imai et al. 1997).
In 2013, there were 234,580 new cases of breast cancer reported in the United States
along with 39,620 deaths (Rebecca and Jemal 2013). Many epidemiological studies suggest that
green tea may have a beneficial effect for breast cancer patients (Li et al. 2014). A 2014 metaanalysis (the application of statistics to data collected and pooled from multiple studies) from
five case-control studies showed a statistically significant 19% reduction in breast cancer risk
among green tea drinkers (Li et al. 2014). However, an earlier meta-analysis of eight studies
concluded that there was not enough statistical support to suggest that green tea had any effect on
reducing breast cancer incidence (Seely et al. 2005). While interesting, these studies are not
conclusive and further research will need to be conducted into the relationship between green tea
and breast cancer.
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There is some compelling epidemiological evidence suggesting that green tea may
provide therapeutic benefits in certain health conditions. While epidemiological studies are
useful to observe effects in the context of daily life, it is impossible to control for all variables.
For example, many of the epidemiological studies conducted on green tea take place in Asia. As
a result, differences between these Asian populations and other populations around the world in
regards to genetics, diet, microbiota, etc. are impossible to completely control for in
epidemiological studies. These differences can confound efforts to analyze green tea's impact in
other populations. The next logical step in evaluating green tea's efficacy as a therapy is to
conduct clinical trials.
Clinical Trials on Green Tea as a Therapy
Clinical trials are prospective studies looking at the effect of an intervention — such as a drug,
surgical procedure, diet, exercise regime, etc. — on human health (Friedman et al. 2010). An
ideal clinical trial is one that has the following characteristics: 1) it is randomized — people are
assigned to the intervention or control group in a random fashion; and 2) it is double-blind —
neither the participants nor the investigators know to which group the participant was assigned
(Friedman et al. 2010). In the United States, a clinical trial funded in part by the National
Institutes of Health (NIH) and/or other government institutions is the gold standard in quality
assurance. Currently, there are only six completed, NIH-funded clinical trials studying the
efficacy of green tea as a preventative or therapeutic in various disorders — prostate cancer,
chronic obstructive pulmonary disease, human papillomavirus (HPV), osteoporosis, chronic
lymphocytic leukemia, and multiple sclerosis. Only three of these studies — examining HPV,
osteoporosis, and chronic lymphoid leukemia — have published their results.
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Cervical cancer is the most common gynecological malignancy globally (Garcia et al.
2014). Human papillomavirus (HPV) infection is implicated in greater than 99% of all cervical
cancer cases (Bosch and de Sanjosé 2003). Previous studies suggested that treatment with green
tea supplements might accelerate clearance of HPV infection (Ahn et al. 2003; Tatti et al. 2008).
In one clinical trial, Garcia et al. (2014) investigated the effects of Polyphenon E, a concentrated
green tea supplement, on prevention of cervical cancer in women with pre-cancerous growth as a
result of HPV infection. Ninety-eight women were enrolled in the study, randomly sorted into
the Polyphenon E group or the placebo group, and followed for four months. The study found no
evidence that Polyphenon E treatment promoted the clearance of HPV infection (Garcia et al.
2014).
Osteoporosis is a degenerative bone disease characterized by lower bone density, which
increases the risk for fractures and breaks (National Institutes of Health 2001). This condition
causes an estimated 1.5 million fractures annually in the United States at a cost of $20 billion per
year (Cooper et al. 2011; Cummings and Melton 2002). Postmenopausal women are four times
more likely to develop osteoporosis than other populations because of a decrease in estrogen
levels (Looker et al. 2010). A clinical trial conducted by Shen et al. (2012) enrolled one hundred
and seventy-one postmenopausal women with osteopenia (lower than normal bone mineral
density and therefore at risk for osteoporosis) to determine whether intervention with green tea
supplements and an exercise regime with tai chi would improve their bone health. There were
four study groups: 1) starch placebo control; 2) green tea supplement (500 mg/day); 3) placebo
and tai chi for 60 minutes, three times per week; and 4) green tea supplement and tai chi (Shen et
al. 2012). The researchers measured calcium metabolism through parathyroid hormone levels,
muscle strength, and the serum levels of two bone turnover markers — bone-specific alkaline
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phosphatase (BAP), which is indicates good bone density, and tartrate-resistant acid phosphatase
(TRAP), which indicates poor bone density (Shen et al. 2012). Over the course of six months,
they observed improved levels of parathyroid hormone and BAP, an improved BAP/TRAP ratio,
and increased muscle strength due to the combination of green tea supplementation and tai chi
(Shen et al. 2012). On the basis of this study, green tea supplementation alone improved BAP
levels within one month, improved the BAP/TRAP ratio within three months, and increased
muscle strength within six months. These results suggest that green tea (and tai chi) may be
effective at maintaining bone mineral density in postmenopausal women (Shen et al. 2012).
Chronic lymphocytic leukemia is the most common form of leukemia, with 15,000 new
cases and 5,000 deaths annually in the United States (Nabhan and Rosen 2014). Many studies
suggest that green tea has a therapeutic effect for leukemia and lymphoma patients (Frankenfeld
et al. 2008; Kuo et al. 2009; Naganuma et al. 2009; Zhang et al. 2008). In this study, forty
patients with asymptomatic, early stage chronic lymphocytic leukemia received Polyphenon E
twice daily (Shanafelt et al. 2013). Following six months of treatment, the researchers saw
significant declines in absolute lymphocyte count and lymphadenopathy, signs that the cancer
was not progressing, in 70% of their patients (Shanafelt et al. 2013). These results suggest that
green tea supplements may be effective at preventing the progression of chronic lymphocytic
leukemia in early stage patients.
While the trials discussed above suggest that green tea may play a role in maintaining
bone mineral density and preventing the progression of leukemia, the mechanism by which green
tea (or green tea supplements) accomplishes this remains unknown. Clinical trials are better at
controlling variables than epidemiological studies, which often rely on self-reporting; however,
clinical trials cannot completely eliminate confounding variables and/or compliance issues.
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Clinical trials are currently the best way to measure drug safety and efficacy. The results of these
studies, while modest, are somewhat encouraging for green tea's future as a clinical therapy.
Biochemistry of Green Tea
The United States Food and Drug Administration (FDA) does not require that the mechanism of
action be understood for drugs before they enter into a clinical trial (Nature Medicine 2010). An
editorial in Nature Medicine, one of the top international medical journals, argues that lack of
knowledge about drug targets and mechanisms hinders the ability to prescribe drugs in a
maximally beneficial manner (Nature Medicine 2010). Within green tea, there are fifteen active
polyphenols known to interact with at least 200 different targets in humans, but the mechanisms
are not well categorized (Figure 2). These targets can be further organized into seven disease
groups, but without clearly defined mechanisms it is impossible to assess green tea's effects
within these categories (Figure 2). For example, there are nine protein targets within the disease
group diabetes, but how green tea polyphenols interact with these proteins and produce
medically beneficial effects is not known (Figure 2). I present below two examples of proposed
mechanisms that will elucidate the complexity and the ill-defined nature of this research.
With respect to cardiovascular disease, researchers have investigated many different
proposed mechanisms for EGCG’s role in disease control and prevention. Some scientists have
highlighted the ability of green tea to reduce the risk of cardiovascular disease by acting as an
anti-thrombotic, anti-oxidant, anti-hypertensive, anti-inflammatory, anti-proliferative, antidiabetic, and anti-mutagenic (Babu and Liu 2008; Basu and Lucas 2007). For example, in terms
of anti-thrombotic action, there is a proposed interaction of EGCG with the enzyme plasminogen
activator inhibitor-1 (PAI-1), a key molecule in the formation of a thrombus (Peng et al. 2008;
Rijken and Lijnen 2009; Vaughan 2005). High levels of PAI-1 have been linked to an increased
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risk for thrombus formation because they preclude the degradation of the extracellular matrix —
the web of fibers and associated fluids between cells — by plasmin (Gils and Declerck 2004).
Elevated PAI-1 has been demonstrated in a number of conditions including heart attack,
coronary artery disease, deep vein thrombosis, and atherosclerosis (Declerck and Gils 2013).
EGCG has been shown to hinder the action of PAI-1 in human cell cultures and this mechanism
is thought to reduce the risk of atherosclerosis by inhibiting thrombus formation following the
rupture of plaque built-up on the arterial wall (Cale et al. 2010; Cao et al. 2013). Thus, inhibition
of PAI-1 by EGCG would reduce the risk of thrombus formation.
As with cardiovascular disease, diabetes research has uncovered multiple potential
mechanisms of action for how EGCG may act upon the endocrine system, metabolism, redox
states, and various cell types to reduce the incidence and impact of Type 2 diabetes and obesity
(Kao et al. 2006). For example, one research group used a diabetic mouse model to examine
EGCG’s effect on glucose tolerance (Ortsäter et al. 2012). After ten weeks, the fasting blood
glucose levels for the control group rose to 14.7 mM and the EGCG supplemented mice saw a
concentration of 9.3 mM, a statistically significant drop (Ortsäter et al. 2012). However, mice
treated with a current diabetic drug — rosiglitazone — had a fasting blood glucose level of only
4.0 mM after ten weeks (Ortsäter et al. 2012). EGCG is less effective than rosiglitazone, but still
produced a statistically significant drop in blood glucose levels in mice, and EGCG may prove to
be a less toxic and cheaper option.
Developing a comprehensive mechanistic characterization of EGCG and the other
compounds in green tea is crucial in determining whether or not green tea will prove an effective
therapy for any health conditions. However, the lack of consensus in the literature makes it
challenging to identify the truly promising actions. In addition, the concentrations of EGCG
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required to achieve even minimally beneficial effects for both atherosclerosis and diabetes are
large and not reasonably achieved through the consumption green tea alone — the most effective
dose of EGCG in the atherosclerosis study described above was 50 µM and in a cell-culture
diabetes study was 10 µM (Table 2, Figure 1; Cao et al. 2013; Kim et al. 2013). In humans, the
largest dose of EGCG for which data are available — the equivalent of at least 180 cups of green
tea, assuming a generous 10 mg of EGCG per cup — only produced a maximum plasma
concentration of just over 6 µM (Table 2, Figure 1). Also, as discussed earlier, the amount of
EGCG in green tea can vary dramatically, which raises a number of questions regarding effective
dosing (United States Department of Agriculture 2013).
The proposed mechanisms discussed above do not begin to scratch the surface of the
potential mechanisms and targets in the literature of EGCG and green tea within the vast array of
human disorders in which it is implicated (Figure 2). Given the numerous potential mechanisms
involved in the cardiovascular system and diabetes, EGCG and other components in green tea
seem to appear everywhere researchers look — suggesting that EGCG may qualify for
classification as a PAIN.
The Bioavailability of Green Tea
Bioavailability is a measure of the amount of a drug that enters into circulation — the higher a
drug’s bioavailability, the greater the drug’s effectiveness (Chow and Liu 2009). Bioavailability
falls under the umbrella field of pharmacokinetics — the study of the fate of drugs upon
administration, for example how much of the drug ends up in circulation or is lost as waste
(Shargel et al. 2012). There have been numerous studies on the bioavailability of polyphenols
such as EGCG (Table 2, Figure 1), and they do no appear to be readily bioavailable in the body
for reasons that are not completely understood (Manach et al. 2004). An important measure of
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bioavailability is the Cmax of a drug, which is the maximum concentration that a drug reaches in
blood plasma (Urso et al. 2002). Pharmacokinetic studies conducted with green tea show a large
variability in the Cmax of EGCG, ranging from 0.02-6.35 µM in blood plasma (Table 2, Figure 1).
The correlation coefficient, r, is a measure of the strength of a relationship between two variables
— the closer the r value is to 1, the stronger the relationship; whereas, another measure of the
relationship between variables, the coefficient of determination, r2, looks at the predictability of
changes in one variable producing consistent changes in another variable— an r2 value closer to
1, means that changes in the independent variable (in our case dose of EGCG) are a better
predictor of changes in the dependent variable (in our case Cmax) (Gerstman 2014). On the basis
of a linear regression analysis, there is a positive relationship between dose of EGCG and plasma
concentration (F1,24 = 28.18; p-value ≤ 0.001; r = 0.73; r2 = 0.54; Figure 1), but the removal of
three clear outliers noticeably reduces this relationship (F1,20 = 11.66; p = 0.003; r = 0.61; r2 =
0.37). This variability of EGCG’s bioavailability is a challenge when attempting to provide
reliable dosing.
The less than ideal relationship between dose and plasma concentration may be related to
the variable amounts of EGCG among similar green tea doses. The USDA Database for the
Flavonoid Content of Selected Foods found that brewed green teas have anywhere between 2.3
mg and 203 mg EGCG per 100 g serving (United States Department of Agriculture 2013). This
variability in the amount of EGCG further suggests that green tea, as a beverage, may prove
ineffective as a medicinal therapy. Even with the generous assumption of 10 mg EGCG per cup
of tea, an unrealistic amount of green tea would be required to achieve the necessary
physiologically levels to see any benefit, as noted in the previous section. It appears impossible
for any individual to drink enough green tea to significantly improve their health outcomes.
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Green Tea and Liver Damage
Given the studies examined thus far, it does not seem possible for the average human to attain
the necessary concentrations of EGCG to experience beneficial health outcomes from drinking
green tea alone (Table 2, Figure 1). Thus, it is reasonable to assume that if EGCG is to be used as
a drug it will most likely be in the form of a concentrated supplement containing high doses of
EGCG. However, there are numerous studies in which researchers have found that high doses of
EGCG can cause liver damage in both humans and rodents (Chen et al. 2010; Emoto et al. 2014;
Galati et al. 2006; Gallo et al. 2013; Goodin 2006; Lambert et al. 2010; Mazzanti et al. 2009;
Molinari et al. 2006; Patel et al. 2013; Salminen et al. 2012; Shanafelt et al. 2013). Some of these
studies describe only a single case and/or potential interference by other medications (Emoto et
al. 2014; Mazzanti et al. 2009), while others involved high concentrations of EGCG and longperiods of exposure (Emoto et al. 2014). All drugs have toxic concentrations; however, at
present, the concentration of and length of exposure to EGCG that would lead to liver damage is
unknown (Emoto et al. 2014). The potential for harmful side effects following prolonged
exposure and/or high doses — greater than 400 mg EGCG per dose, or about 20 cups of green
tea, in humans typically for over a month — raise concerns over whether EGCG could ever be
used for therapeutic purposes (Emoto et al. 2014).
Conclusions: Green Tea, Panacea or PAIN?
Is green tea a panacea or a PAIN? Scientists really do not know. The research into green tea’s
role as a drug is burgeoning, conflicting, and inconclusive. There is strong epidemiological
evidence from multiple large studies suggesting that drinking green tea improves health
outcomes of certain populations (Hertog et al. 1995; Iso et al. 2006; Kris-Etherton and Keen
2002; Kuriyama et al. 2006; Mozaffari-Khosravi et al 2013; Odegaard et al. 2008; Sesso et al.
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1999; Yang et al 2004). However, clinical trials funded by the National Institutes of Health are
very few in number and demonstrate only modest results (Garcia et al. 2014; Shanafelt et al.
2013; Shen et al. 2012). The bioavailability of EGCG and other green tea polyphenols is poorly
understood (Manach et al. 2004), and the wide range of EGCG present in green tea raises
concerns that the dose is not consistent between cups (United States Department of Agriculture
2013). Laboratory studies often involve large doses of concentrated EGCG that are well beyond
the amounts that could be consumed by ingestion and there are some warning signs that large
doses of EGCG may lead to liver damage (Emoto et al. 2014; Lambert and Yang 2003). Finally,
there is concern about the specificity of EGCG and other polyphenols found in green tea, as
many of them may turn out to be pan-assay interfering compounds (Baell 2010).
The health claims regarding green tea made to the general public are clearly over-stated.
While epidemiological studies look promising, clinical and laboratory trials to date are not
compelling, requiring large doses and producing poorly defined benefits. Enjoying a few cups of
green tea daily will not harm you, but it probably will not save you from cardiovascular disease,
cancer, diabetes, or any other disease. In the absence of convincing mechanisms and consistent
dosing, it is difficult to see green tea, or any of its components, rising to pharmaceutical status.
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Table 1. Recent research studies involving green tea and health.
Study

Organism/Cells
Examined

Disease/Condition

Discusses
Mechanism

Discusses
Bioavailability

Discusses
Dose*

Fatemi et al.
2014

Rats

Burns

No

N/A, topical

No

Neturi et al.
2014

Humans

Streptococcus
mutans count in
mouth

No

N/A, oral rinse

No

Mice

Wrinkles

No

N/A, topical

No

No

No

7 cups per
day

Yes

No

No

Antibiotic
Properties

No

N/A

No

Osteosarcoma

Yes

No

No

Influenza

No

No

Two cups
per week
minimum

No

No

No

Lee et al.
2014b
Ohmori et al.
2014
Liu et al. 2015
Anita et al.
2014
Jiang et al.
2014

Humans
Human Liver
Cells in Culture
Cariogenic
Bacteria in
Culture
Human
Osteosarcoma
Cells in Culture

Delabre et al.
2015

Humans

Audomkasok
et al. 2014

Mice

Ahn et al.
2014

Rats

Huang et al.
2015

Rabbits

Gu et al. 2014

Rats

Liu et al. 2014

Human Aortic
Smooth Cells in
Culture

Khan et al.
2014

Rats

Nasri et al.
2013

Rats

Suthar et al.
2014

Human
Erythrocytes in
Culture

Coronary Artery
Disease
Cholesterol
Metabolism

Malaria
(Plasmodium
berghei)
Cisplatin-Induced
Nephrotoxicity
Autologous
Chondrocyte
Implantation
Chronic
Unpredictable Mild
Stress-Induced
Cognitive
Impairment

No

No

No

Yes

No

No

Yes

No

No

Atherosclerosis

Yes

No

No

Yes

No

No

No

No

No

Yes

No

No

DoxorubicinInduced
Cardiotoxicity
Contrast MediaInduced Acute
Renal Damage
Bisphenol AInduced Oxidative
Stress

38

Table 1 (continued). Recent research studies involving green tea and health.
Study

Organism of
Study

Disease/Condition

Discusses
Mechanism

Discusses
Bioavailability

Discusses
Dose*

Jeon et al.
2014

Bacteria from
Human Skin
Wounds in
Culture

Bacterial
(Pseudomonas
aeruginosa and
Escherichia coli)
Infection of Skin
Wounds

No

No

No

Bacterial
Cultures

Antibacterial

No

No

No

Rats

Nonalcoholic
Steatohepatitis

No

No

No

Lodhi et al.
2014

Rats

Chronic EthanolInduced
Hepatotoxicity

Yes

No

No

Chakraborty et
al. 2014

Rats

CyclophosphamideInduced Myocardial
Damage

Yes

No

No

Zhao et al.
2014

Rat Embryo
Spinal Cord
Neurons in
Culture

Spinal Cord
Neuronal Oxidative
Damage

Yes

No

No

Shin et al.
2014

Rats

Postsurgical
Adhesions

Yes

No

No

Saleh et al.
2014

Human Blood
Cells from
Breast Cancer
Patients in
Culture

Peripheral Blood
Mononuclear Cells
Proliferation in
Breast Cancer

No

No

No

Lee et al.
2014a

Human Retinal
Pigmented
Epithelial Cells
in Culture

Ocular Angiogenic
Disease

Yes

No

No

Bashir et al.
2014
MirandaHenriques et
al. 2014

* In public health relevant units such as ounces, cups, or grams of tea leaves.
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Table 2. The varied bioavailability of EGCG.
Amount of EGCG
37 mg
50 mg
63 mg
67 mg
75 mg
100 mg
105 mg
110 mg
112 mg
134 mg
200 mg
200 mg
200 mg
200 mg
214 mg
219 mg
329 mg
400 mg
400 mg
400 mg
600 mg
800 mg
800 mg
800 mg
1200 mg
1600 mg
*Found in: Feng 2006

Cmax in Plasma
0.020 µM
0.260 µM
0.330 µM
0.170 µM
0.080 µM
0.410 µM
0.055 µM
0.260 µM
0.125 µM
0.080 µM
0.160 µM
0.710 µM
0.680 µM
0.150 µM
0.080 µM
0.710 µM
0.700 µM
0.240 µM
1.100 µM
1.240 µM
0.370 µM
0.960 µM
4.950 µM
2.100 µM
0.113 µM
6.350 µM

Study/Review
Warden et al. 2001*
Ullmann et al. 2003*
Unno et al. 2005
Lee et al. 2002
Del Rio et al. 2010
Ullmann et al. 2003*
Stalmach et al. 2009
Yang et al. 1998
Williamson et al. 2011
Renouf et al. 2010
Chow et al. 2001*
Ullmann et al. 2004*
Ullmann et al. 2003*
Meng et al. 2002*
Henning et al. 2004
Yang et al. 1998
Yang et al. 1998
Chow et al. 2001*
Ullmann et al. 2004*
Ullmann et al. 2003*
Chow et al. 2001*
Chow et al. 2001*
Ullmann et al. 2004*
Ullmann et al. 2003*
Lee et al. 1995
Ullmann et al. 2003*
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Figure Legends
Figure 1. The relationship between Cmax and EGCG dose in humans, based on data obtained
from the twenty-six studies listed in Table 2 (r = 0.73, r2 = 0.54 for all studies; r = 0.61, r2 = 0.37
following removal of outliers, indicated by black diamonds).

Figure 2. The main targets for green tea polyphenols in humans. Fifteen green tea polyphenols
(diamonds) are linked to two-hundred protein targets (circles) via lines (grey), which are divided
into seven disease categories (from Zhang et al. 2014).
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Figure 2

